Fate Therapeutics, Inc. (FATE)
| Market Cap | 257.02M +35.1% |
| Revenue (ttm) | 6.49M -23.4% |
| Net Income | -126.00M |
| EPS | -1.05 |
| Shares Out | 119.82M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 591,065 |
| Open | 2.170 |
| Previous Close | 2.170 |
| Day's Range | 2.120 - 2.230 |
| 52-Week Range | 0.950 - 3.230 |
| Beta | 2.53 |
| Analysts | Buy |
| Price Target | 5.74 (+167.79%) |
| Est. Earnings | Nov 12, 2026 |
About FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tum... [Read more]
Financial Performance
In 2025, Fate Therapeutics's revenue was $6.65 million, a decrease of -51.24% compared to the previous year's $13.63 million. Losses were -$136.32 million, -26.82% less than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for FATE stock is "Buy." The 12-month stock price target is $5.74, which is an increase of 167.79% from the latest price.
News
Fate Therapeutics presents updated FT819 data at Kidney Week
Fate Therapeutics (FATE) announced updated Phase 1 clinical data for FT819, its off-the-shelf, available on-demand, anti-CD19 CAR T-cell product candidate, in patients with systemic lupus erythematosu...
Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026
Active LN patients in the Phase 1 study treated with FT819 and the less-intensive conditioning (bendamustine) regimen selected for the RECLAIM-LN study achieved 100% renal response at Month 6, with ap...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent s...
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent s...
Fate Therapeutics announces CIRM awarded it a $15M grant
Fate Therapeutics (FATE) announced that the California Institute for Regenerative Medicine, CIRM, has awarded the Company a $15M grant, through its CLIN2 program, to support the clinical development o...
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus Nephritis
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
SAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent ...
Fate Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The conference highlighted a scalable, cost-effective CAR T platform with strong safety and efficacy data, especially for FT819 in lupus nephritis. Phase II is underway with promising early results, aiming for a 30%-40% CRR and broad future expansion.
Fate Therapeutics announces clinical data from FT819 study
Fate Therapeutics (FATE) announced clinical data from its off-the-shelf anti-CD19 CAR T-cell product candidate FT819, and pre-clinical data from its off-the-shelf anti-CD19 and CD38 CAR T-cell product...
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting
SAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent ...
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent ...
Fate Therapeutics reports Q2 EPS (25c), consensus (26c)
Reports Q2 revenue $2.08M, consensus $1.27M. “Dosing of the first patient in RECLAIM-LN, our Phase 2 potentially registrational trial, is an exciting milestone as we work to address significant unmet…
Fate Therapeutics price target raised to $3.50 from $2.50 at Wells Fargo
Wells Fargo raised the firm’s price target on Fate Therapeutics (FATE) to $3.50 from $2.50 and keeps an Equal Weight rating on the shares. With first pt dosed in the…
Fate Therapeutics intiates first patient in RECLAIM-LN trial
Fate Therapeutics (FATE) highlighted the initiation of and treatment of the first patient in RECLAIM-LN, its Phase 2 potentially registrational clinical trial of FT819 in patients with refractory mode...
Fate Therapeutics price target raised to $8 from $6 at Piper Sandler
Piper Sandler raised the firm’s price target on Fate Therapeutics (FATE) to $8 from $6 and keeps an Overweight rating on the shares. The firm notes Fate initiated the registrational…
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated as an outpatient w...
Fate Therapeutics Quarterly report: Q2 2026
Fate Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
Fate Therapeutics Earnings release: Q2 2026
Fate Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Fate Therapeutics announces FDA clearance of FT839 IND application
Fate Therapeutics (FATE) announced that the FDA has cleared its investigational new drug, or IND, application for FT839, the company’s next-generation, off-the-shelf CAR T-cell product candidate engin...
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent s...
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent ...
Fate Therapeutics Appoints Laura Hamill to Board of Directors
Accomplished global commercial operations leader brings deep experience launching and scaling biopharmaceutical products as Fate advances its pipeline toward commercialization Accomplished global comm...
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
FT819 off-the-shelf CAR T-cell therapy product candidate continues to broaden patient access with 21 SLE patients now treated, including as outpatient administration in community hospitals Continued d...